Recent reviews of azathioprine induced hepatic veno-occlusive disease in recipients of a renal transplant suggest that this poorly recognised drug reaction occurs predominantly in patients with autoimmune dysfunction' 2 or among those with preexisting liver disease.' Our observation of a patient with rheumatoid arthritis (RA) and chronic hepatic necroinflammatory disease of uncertain aetiology, who was found to have histological features of hepatic veno-occlusive disease following the use of azathioprine, further supports this position.
Case report
In 1983 a 59 year old man with a history of remote alcohol abuse and duodenal ulceration reported the onset of polyarticular pain and swelling. Evaluation showed symmetrical synovial thickening, juxta-articular osteopenia and erosions, and a positive rheumatoid factor. Aspirin and numerous other non-steroidal anti-inflammatory drugs were given, without relief of symptoms. Later trials of sodium aurothiomalate, hydroxychloroquine, D-penicillamine, and prednisone were similarly ineffective.
Accepted for publication 24 terised by the triad of jaundice, hepatomegaly or right upper quadrant abdominal pain, and ascites or sudden weight gain.5 The diagnosis is difficult to establish. The spectrum of presenting symptoms is wide, ranging from mild abdominal discomfort to liver failure and death.1 2 6 Hepatic biochemical abnormalities are non-specific. Also, it is difficult to attribute the liver dysfunction exclusively to azathioprine in most subjects in whom it is used because of the simultaneous administration of other potentially hepatotoxic drugs.
Further confusing the issue is the intrinsic hepatic 10 but it has been reported in simple RA only rarely.9 11 12 Similarly, the prevalence of primary biliary cirrhosis is higher in Sjogren's syndrome complicating RA than in RA alone. 19 Katzka and colleagues described the onset of hepatomegaly, scleral icterus, and increased alkaline phosphatase and total bilirubin values after one year of azathioprine treatment (50 mg daily) in a man with inactive systemic lupus erythematosus who had undergone renal transplantation. Symptoms resolved upon cessation of azathioprine and recurred upon rechallenge.2 Repeat liver biopsies were not performed in either of these patients. The role of azathioprine in the induction of veno-occlusive disease in systemic lupus erythematosus is brought into question by Pappas et al, however, who reported the development of clinical evidence of hepatic dysfunction in concert with histological evidence of veno-occlusive disease in a young woman with active systemic lupus erythematosus who had neither undergone renal transplantation nor received azathioprine. A brief trial of azathioprine failed to affect her ascites, and repeat liver biopsy showed no significant changes following the azathioprine treatment. The authors concluded that the pathogenesis of veno-occlusive disease in systemic lupus erythematosus is unknown but postulated that it may be related to underlying vasculitis.20
The development of azathioprine induced hepatic veno-occlusive disease has been associated with either pre-existing autoimmune dysfunction or liver damage,1 2 but a mechanism for the establishment of this vascular abnormality remains unknown. The presence of both immumological defects and incidental liver damage (as a result of possible viral hepatitis or the effects of alcohol ingestion, or both) in this case supports this position, but it unfortunately does not provide a better definition of the pathogenesis of veno-occlusive disease. It seems unlikely that RA alone contributes to the establishment of this disorder. Despite years of experience with azathioprine in RA, veno-occlusive disease has never previously been reported in this population.2' Although no true association between these entities may in fact exist, it is also possible that the lack of more frequent recognition of azathioprine induced veno-occlusive disease in RA reflects the usual benignity of hepatic pathology in RA,7 as well as the subtle histological features and variable presenting symptoms which may characterise hepatic venoocclusive disease.1 2 6 Additionally, the role of preexisting abnormalities of hepatic structure or function, perhaps resulting in altered metabolism of azathioprine and the subsequent development of veno-occlusive disease independent of autoimmune phenomena, cannot be excluded.
Thus administration of azathioprine should be attended with knowledge of the serious consequences that may occur with it use. It should be discontinued immediately in any patient who develops hepatic biochemical abnormalities, hepatomegaly, or other clinical evidence of portal hypertension, and a liver biopsy should be performed to confirm the presence of veno-occlusive disease. Heightened awareness of this potentially fatal complication in patients with RA who are treated with azathioprine may increase the frequency of its diagnosis. 
